We are live on
!
Find out more
RhumbLine Advisers Portfolio holdings
AUM
$117B
1-Year Est. Return
29.66%
This Fund
S&P 500
This Quarter
Est. Return
+9.63%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.92%
AUM
$59.8B
AUM Growth
+$5.07B
(+9.3%)
Cap. Flow
+$518M
Cap. Flow
% of AUM
0.87%
Top 10 Holdings %
Top 10 Hldgs %
18.08%
Holding
2,992
New
38
Increased
2,357
Reduced
537
Closed
43
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$68M |
| 2 |
Truist Financial
TFC
|
+$55.9M |
| 3 |
ServiceNow
NOW
|
+$33.3M |
| 4 |
Uber
UBER
|
+$21.4M |
| 5 |
Las Vegas Sands
LVS
|
+$15.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$119M |
| 2 |
STI
SunTrust Banks, Inc.
STI
|
+$55.9M |
| 3 |
Apple
AAPL
|
+$48.3M |
| 4 |
iShares TIPS Bond ETF
TIP
|
+$22M |
| 5 |
VIAB
Viacom Inc. Class B
VIAB
|
+$16.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.57% |
| 2 | Financials | 15.53% |
| 3 | Healthcare | 13.38% |
| 4 | Consumer Discretionary | 10.07% |
| 5 | Industrials | 9.99% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
SNR
2076
DELISTED
NEW SENIOR INVESTMENT GROUP INC.
SNR
| $1.02M | ﹤0.01% |
132,950
+5,695
| +4% | +$42.3K |
|
|
STFC
2077
DELISTED
State Auto Financial Corp
STFC
| $1.02M | ﹤0.01% |
32,799
+357
| +1% | +$11.5K |
|
2078
Intellia Therapeutics
NTLA
$1.53B
| $1.02M | ﹤0.01% |
69,274
+3,229
| +5% | +$44.9K |
|
2079
Nicolet Bankshares
NIC
$3.65B
| $1.01M | ﹤0.01% |
13,735
+801
| +6% | +$56.5K |
|
2080
NRC Health Common Stock
NRC
$432M
| $1.01M | ﹤0.01% |
15,364
+335
| +2% | +$20.5K |
|
|
LCI
2081
DELISTED
Lannett Company, Inc.
LCI
| $1.01M | ﹤0.01% |
28,662
+1,297
| +5% | +$52.7K |
|
|
FFWM
2082
DELISTED
First Foundation Inc
FFWM
| $1.01M | ﹤0.01% |
57,983
+850
| +1% | +$13.7K |
|
2083
Peoples Bancorp
PEBO
$1.5B
| $1.01M | ﹤0.01% |
29,096
+238
| +0.8% | +$7.79K |
|
|
PFC
2084
DELISTED
Premier Financial Corp. Common Stock
PFC
| $1.01M | ﹤0.01% |
31,965
+186
| +0.6% | +$5.61K |
|
|
CTT
2085
DELISTED
CATCHMARK TIMBER TRUST, INC.
CTT
| $1.01M | ﹤0.01% |
87,687
+4,125
| +5% | +$47K |
|
|
PS
2086
DELISTED
Pluralsight, Inc. Class A Common Stock
PS
| $1.01M | ﹤0.01% |
58,483
+876
| +2% | +$14.9K |
|
|
EIDX
2087
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
| $998K | ﹤0.01% |
17,384
+729
| +4% | +$36.1K |
|
2088
QCR Holdings
QCRH
$1.72B
| $993K | ﹤0.01% |
22,630
+302
| +1% | +$12.3K |
|
2089
Northern Oil and Gas
NOG
$2.15B
| $992K | ﹤0.01% |
42,386
+1,723
| +4% | +$34.1K |
|
2090
First Financial Corp
THFF
$979M
| $992K | ﹤0.01% |
21,691
-10
| -0% | -$441 |
|
2091
BridgeBio Pharma
BBIO
$16.1B
| $989K | ﹤0.01% |
28,228
+3,696
| +15% | +$102K |
|
2092
Bank of Marin Bancorp
BMRC
$472M
| $989K | ﹤0.01% |
21,964
+99
| +0.5% | +$4.38K |
|
2093
TETRA Technologies
TTI
$1.25B
| $989K | ﹤0.01% |
504,729
+25,522
| +5% | +$41.1K |
|
|
TVRD
2094
Tvardi Therapeutics
TVRD
$25M
| $986K | ﹤0.01% |
1,699
+137
| +9% | +$96.1K |
|
2095
Madrigal Pharmaceuticals
MDGL
$11.9B
| $982K | ﹤0.01% |
10,779
+603
| +6% | +$58.5K |
|
|
TSC
2096
DELISTED
TriState Capital Holdings, Inc.
TSC
| $979K | ﹤0.01% |
37,478
+247
| +0.7% | +$5.88K |
|
|
HUD
2097
DELISTED
Hudson Ltd. Class A Common Shares
HUD
| $977K | ﹤0.01% |
63,693
+567
| +0.9% | +$7.39K |
|
2098
Parsons
PSN
$5.1B
| $972K | ﹤0.01% |
23,541
+1,017
| +5% | +$38K |
|
2099
Alaunos Therapeutics
TCRT
$4.93M
| $971K | ﹤0.01% |
1,371
+22
| +2% | +$15.1K |
|
|
RRD
2100
DELISTED
RR Donnelley & Sons Co.
RRD
| $969K | ﹤0.01% |
245,257
+12,853
| +6% | +$50.8K |
|
Similar funds
VAM
RhumbLine Advisers's Q4 2019 Portfolio in Review
As of Q4 2019, RhumbLine Advisers held 2,992 positions worth $59.8B, up 9.3% from $54.7B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
Trading was light in Q4 2019: portfolio turnover was 2.7%. RhumbLine Advisers opened 38 new positions and exited 43, leaving the 2,992-position portfolio largely intact.
By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 19% a quarter earlier, followed by Financials and Healthcare.
- RhumbLine Advisers's largest Q4 2019 buy was Envista: 126,664 shares worth $3.75M.
- RhumbLine Advisers added most to Bristol-Myers Squibb in Q4 2019, an estimated $68M increase.
- RhumbLine Advisers's biggest Q4 2019 reduction was Apple, cutting an estimated $48.3M.
- RhumbLine Advisers fully exited Celgene Corp in Q4 2019, selling an estimated $119M.
- RhumbLine Advisers's ten largest holdings make up 18% of its $59.8B portfolio in Q4 2019.
- RhumbLine Advisers opened 38 new positions and closed 43 in Q4 2019.
- RhumbLine Advisers's portfolio value rose 9.3% quarter-over-quarter to $59.8B.
Based on RhumbLine Advisers's 13F filing for Q4 2019, filed 5 Feb 2020.